SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2025, and provided a business update.
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Seeking Alpha / 31 minutes from now 1 Views
Comments